Relative Bioavailability of Two Different BI 690517 Formulations as Well as the Effect of Multiple Doses of Probenecid on the Single Dose Pharmacokinetics of BI 690517 Following Oral Administration in Healthy Male and Female Subjects (a Randomised, Open-label, Three-way Crossover Trial)
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Probenecid (Primary) ; Vicadrostat (Primary)
- Indications Heart failure; Renal failure
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 09 Jan 2025 Status changed from active, no longer recruiting to completed.
- 13 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2024 Planned End Date changed from 20 Dec 2024 to 23 Dec 2024.